Home Hot keywords

Search Modes

搜索结果

perjeta domain
Perjeta is a cancer medicine for treating adults with 'HER2-positive' breast cancer (where a protein called HER2 is found on the cancer cells). Perjeta is used ...
Agency product number: EMEA/H/C/002547
Therapeutic area (MeSH): Breast Neoplasms
Active substance: pertuzumab
Perjeta is indicated for use in combination with trastuzumab and chemotherapy in ... dimerization domain (subdomain II) of the human epidermal growth factor ...
作者:M Capelan2013被引用次数:139Pertuzumab is a humanized monoclonal antibody that binds to the extracellular domain II of HER2. Its mechanism of action is complementary to trastuzumab, ...
Neoadjuvant: Administer PERJETA, trastuzumab or trastuzumab ... Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human.
36 页·1 MB
作者:B Nami2018被引用次数:70Pertuzumab specifically interacts with the subdomain II of HER2 extracellular domain, sterically blocking a binding pocket necessary for ...
作者:G Fuentes2011被引用次数:64The anti-Her2 monoclonal antibody trastuzumab binds to domain IV of Her2, a region that is not involved in receptor dimerization and is thought ...
Neoadjuvant: Administer PERJETA, trastuzumab, and docetaxel by ... 435 Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human.
24 页·839 KB
286 dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein. 287 (HER2). Pertuzumab is produced by recombinant DNA ...
Trastuzumab is another monoclonal antibody against HER2; its epitope is the domain where HER2 binds to another HER2 protein. The two mAbs together prevent HER2 ...
CAS Number: 380610-27-5
Other names: 2C4
Target: HER2
ATC code: L01FD02 (WHO)
图片
选择图片即可提供反馈
提供反馈

google search trends